Tadakazu Hisamatsu - Concepedia

Author

Tadakazu Hisamatsu

Also Known As

Akira Andoh, DIAMOND2 Study Group, Haruhiko Ogata, Hiroshi Nakase, Hisamatsu, T., Ichiro Hirata, Katsuyoshi Matsuoka, Matsuoka, Katsuyoshi, Miki Miura, Sakiko Hiraoka

621

Publications

14K

Citations

H-Index

125

Concepts

All Affiliations

Keio University Kyorin University Kitasato Institute Hospital Kitasato University Toho University

About

Tadakazu Hisamatsu is an author at Keio University specializing in medicine, immunology, and inflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	65	5.1K
2	Allergy	8	8	650
3	Health Sciences	4	4	128
4	Engineering	2	2	28
5	Public Health	1	1	28

Tadakazu Hisamatsu

146

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis Bruce E. Sands, William J. Sandborn, Remo Panaccione, New England Journal of Medicine	2019	1.1K
CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells Tadakazu Hisamatsu, Manabu Suzuki, Hans-Christian Reinecker, Gastroenterology InflammationDysbiosisAntibacterial FactorMucosal ImmunologyImmunology	2003	631
Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis Nobuhiko Kamada, Tadakazu Hisamatsu, Susumu Okamoto, Journal of Clinical Investigation	2008	589
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease Taku Kobayashi, Shosuke Okamoto, Tadakazu Hisamatsu, Gut	2008	554
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials Geert D’Haens, Remo Panaccione, Filip Baert, The Lancet RheumatologyInduction TherapyImmunologyGastroenterologyClinical Trials	2022	362
A Single Strain of Clostridium butyricum Induces Intestinal IL-10-Producing Macrophages to Suppress Acute Experimental Colitis in Mice Atsushi Hayashi, Toshiro Sato, Nobuhiko Kamada, Cell Host & Microbe InflammationProbioticDysbiosisMucosal ImmunologyImmunology	2013	318
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial Marc Ferrante, Remo Panaccione, Filip Baert, The Lancet Fortify Maintenance TrialRheumatologyWithdrawal Phase 3GastroenterologyTreatment Option	2022	294
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial Takayuki Matsumoto, Satoshi Motoya, Kenji Watanabe, Journal of Crohn s and Colitis	2016	234
Imbalance of NKp44+NKp46− and NKp44−NKp46+ Natural Killer Cells in the Intestinal Mucosa of Patients With Crohn's Disease Tetsuro Takayama, Nobuhiko Kamada, Hiroshi Chinen, Gastroenterology InflammationChronic Inflammatory DiseasesMucosal ImmunologyInnate Immune SystemImmunology	2010	227
Abnormally Differentiated Subsets of Intestinal Macrophage Play a Key Role in Th1-Dominant Chronic Colitis through Excess Production of IL-12 and IL-23 in Response to Bacteria Nobuhiko Kamada, Tadakazu Hisamatsu, Susumu Okamoto, The Journal of Immunology InflammationCytokineChronic ColitisAutoimmune DiseaseEnteric Bacteria Recognition	2005	217

Page 1